Skip to content

An exploratory clinical trial of efficacy and safety of a two-target implantable neurostimulation system for the Treatment of Autism Spectrum Disorder (ASD)

Clinical study on efficacy and safety of dual-target DBS treatment of autism

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084888
Enrollment
Unknown
Registered
2024-05-27
Start date
2023-09-06
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism

Interventions

Single unit:(nucleus accumbens - forelimb of internal capsule) dual-target deep brain stimulation

Sponsors

The 900th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.Male or Female patients between age 7 to 18; 2.Meets the diagnosis of Autism Spectrum Disorder (ASD) as defined by the DSM-5; 3.Condition or disease duration >= 5 years, and patients have received systematic behavioral therapies or training that have been ineffective, or cannot tolerate the training; 4.The legal guardian agrees to the patient's treatment with DBS in the nucleus accumbens (NAc) and anterior limb of the internal capsule (ALIC) and signs an informed consent form after being fully informed of the description of the purpose and content of the study, the intended treatment, and the risks.

Exclusion criteria

Exclusion criteria: 1. Patients with substance dependence in the past 6 months, except tobacco; 2. Patients with severe or unstable cardiovascular, respiratory, hepatic, renal, hematologic, endocrine, neurological, or other systemic disorders; 3. Patients who have had a cochlear implant, pacemaker, cardiac defibrillator, have had a unilateral or bilateral implant of the same type, or have had any other surgical procedure within six months that in the opinion of the investigator would have an effect on the trial; 4. Patients who are currently participating in or have participated in a clinical trial of another drug or medical device within 3 months prior to screening; 5.Other patients who, in the opinion of the investigator, are not suitable for participation in this clinical study.

Design outcomes

Primary

MeasureTime frame
Changes in Autism Behavior Checklist (AuBC) scores;

Secondary

MeasureTime frame
Changes in Autism Behavior Checklist (AuBC) scores at the end of 1 and 3 months after DBS-ON compared to baseline values;Changes in Childhood Autism Rating Scale (CARS) scores at the end of 1, 3, and 6 months after DBS-ON compared to baseline values;Changes in Repetitive Behaviors Scale - Revised (RBS-R) scores at the end of 1, 3, and 6 months after DBS-ON compared to baseline values;Changes in Aberrant Behavior Checklist (AbBC) scores at the end of 1, 3, and 6 months after DBS-ON compared to baseline values;Changes in Autism Treatment Evaluation Checklist (ATEC) scores at the end of 1, 3, and 6 months after DBS-ON compared to baseline values;Changes in Clinical Global Impression Scale - Severity (CGI-S) scores at the end of 1, 3, and 6 months after DBS-ON compared to baseline values;Changes in Clinical Global Impression Scale - Improvement (CGI-I) scores at the end of 1, 3, and 6 months after DBS-ON compared to baseline values;Changes in Global Assessment of Functioning (GAF) scores at the end of 1, 3, and 6 months after DBS-ON compared to baseline values;Changes in social and behavioral activities of the patients compared to baseline were evaluated by video at the end of 1, 3, and 6 months after DBS-ON;

Countries

China

Contacts

Public ContactBangqing Yuan

The 900th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force

ybqing4157@163.com+86 138 0950 4157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026